A New Paradigm for Personalized Medicine and Companion Diagnostics: The Contract Diagnostics Organization

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Unknown venue

• Publication date

  2012-08-10

• Fields of study

  Medicine, Business

• Identifiers
  DOI 10.2174/2210289201203010052
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• HER2 testing in gastric cancer: a practical approach

  2012cited by this paper
• HER-2/neu Overexpression is an Independent Prognostic Factor for Intestinal-type and Early-stage Gastric Cancer Patients

  2012cited by this paper
• Personalized Medicine — Trends in Molecular Diagnosticsy

  2012cited by this paper
• Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

  2012cited by this paper
• A challenging drug development process in the era of personalized medicine.

  2011influential reference
• Sentinel Surveillance of Influenza-Like-Illness in Two Cities of the Tropical Country of Ecuador: 2006–2010

  2011cited by this paper
• Personalized medicine--trends in molecular diagnostics: exponential growth expected in the next ten years.

  2011cited by this paper
• Using Pharmacogenetics in Real Time to Guide Warfarin Initiation: A Clinician Update

  2011cited by this paper
• ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.

  2010cited by this paper
• What is a biomarker? Research investments and lack of clinical integration necessitate a review of biomarker terminology and validation schema

  2010cited by this paper
• EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

  2010cited by this paper
• Progress towards personalized medicine.

  2010cited by this paper
• The path to personalized medicine.

  2010cited by this paper
• The Case for Personalized Medicine

  2009cited by this paper
• New era of personalized medicine: a 10-year anniversary.

  2009cited by this paper
• Current and emerging tests for the laboratory monitoring of chronic myeloid leukaemia and related disorders.

  2008cited by this paper
• Hospital Admissions Associated with Adverse Drug Reactions: A Systematic Review of Prospective Observational Studies

  2008cited by this paper
• Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

  2007cited by this paper
• KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

  2006cited by this paper
• The role of companion diagnostics in the development and use of mutation-targeted cancer therapies

  2006cited by this paper
• Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

  2005cited by this paper
• Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

  2005cited by this paper
• New era of personalized medicine: targeting drugs for each unique genetic profile

  1999cited by this paper
• Efficacy of fluorescence in situ hybridization for detecting PML/RARA gene fusion in treated and untreated acute promyelocytic leukemia.

  1994cited by this paper
• Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions.

  1992cited by this paper

• Optimal co-development contracts for companion diagnostics

  2024cites this paper
• Companion Diagnostics Development and Commercialization : A Case Study from the Diagnostics’ Perspective

  2015cites this paper